Patent intelligence · US
US 10328095
Resorbable oxidized cellulose embolization microspheres
Resorbable oxidized cellulose embolization microspheres
Patent details — US 10328095
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 25, 2019
- Expiration
- Jun 20, 2039
- Applicant
- Covidien LP
- Claims
- 19
- CPC classes
- A61K, A61K31/717
Quick answer
US 10328095 (Resorbable oxidized cellulose embolization microspheres) is held by Covidien LP. Status: granted. Granted Jun 25, 2019. Expires Jun 20, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Covidien LP
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/717
More from Covidien LP
Related pharmaceutical patents in our USPTO index.
-
US 12364708
Injectable scaffold for treatment of intracranial aneurysms and related technology
granted -
US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted -
US 12336973
Cancer therapeutic compositions and methods targeting DNAse1L3
granted -
US 12329909
Airway management systems for pulmonary disorder treatment
granted -
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12185909
System and method for cleansing segments of a luminal network
granted -
US 12150461
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted
Frequently asked questions
What is US patent 10328095?
US 10328095 (Resorbable oxidized cellulose embolization microspheres) is held by Covidien LP. Status: granted. Granted Jun 25, 2019. Expires Jun 20, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10328095?
Covidien LP is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 193 pharmaceutical patents for this assignee.
When does US 10328095 expire?
Our index shows an expiration date of Jun 20, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.